Stocksigma LogoStocksigma Logo

Q-Line Biotech Secures 25% Royalty Reduction in Amended Agreement with Boule Medical

Q-Line Biotech entered an amended license agreement with Sweden's Boule Medical AB for diagnostic reagents and haematology analyzers

Q-Line Biotech Secures 25% Royalty Reduction in Amended Agreement with Boule Medical

Q-Line Biotech Ltd 路 Press Release 路 02 Sept 2026, 11:24 pm

Q-Line Biotech Secures 25% Royalty Reduction in Amended Agreement with Boule Medical Q-Line Biotech entered an amended license agreement with Sweden's Boule Medical AB for diagnostic reagents and haematology analyzers. A key commercial benefit is a 25% reduction in license and royalty costs payable to Boule, effective 1st Jul'26. The revised framework includes rationalized minimum purchase commitments, extended payment terms, and volume-linked benefits, enhancing Q-Line's cost efficiency in price-sensitive institutional markets. The agreement has an initial 5-year term, extendable by another 5 years, positioning the company for deeper market penetration, higher instrument placements, and increased recurring reagent volumes.

Original exchange filing (PDF)

More announcements from Q-Line Biotech Ltd

All Q-Line Biotech Ltd announcements